SHINE app expands response research to include COVID-19
The scope of the SHINE app developed by MediBloc and KT’s Infectious Disease Research Consortium will be expanded from flu to COVID-19 with support from the Bill & Melinda Gates Foundation.
Existing users of the SHINE app can be aware of the occurrence of surrounding diseases such as COVID-19, and if they experience flu-like symptoms such as fever, headache, and cough and use the app, they can check their risk for infectious diseases. All app data is safely stored using MediBloc’s Panacea blockchain. With their approval, users can contribute their data to research projects addressing the spread of infectious diseases.
About 18,000 people participated in the study and entered data on COVID-19 and the flu after the app was released last year with the research participation status of study participants recorded in MediBloc’s blockchain Panacea. Up to this year, more than 10,000 data were recorded.
Currently, the SHINE app has added a function that allows one to enter PCR test results, vaccination history, and vaccine adverse reactions.
You can participate in collecting infectious disease research data using the SHINE app in two ways. First is through a clinical study conducted by Professor Kim Woo-joo’s team at Korea University Guro Hospital with three hospitals in Korea (Korea University Ansan Hospital, Chungbuk National University Hospital, and Hallym University Kangnam Sacred Heart Hospital). Patients who visit the hospital are asked for their consent to participate in the study and have infectious diseases accurately diagnosed through respiratory sample collection tests. Afterwards, the infectious disease symptom data input by the study participants are collected and used for research.
Second, ordinary people who do not participate in clinical research can also download the SHINE app from the Apple App Store, One Store, and the SHINE homepage and can participate. Detailed information on this study and the benefits of participation can be found on the SHINE website.
Song Jae-ho, vice president of KT AI/DX’s convergence business division said, “KT wants to find a solution to prevent the spread of new and variant infectious diseases, including flu and COVID-19. We ask for the active participation of many people in research so that the technology to respond to infectious diseases using Korea’s ICT capabilities can contribute to global quarantine.”
Dr. Allen Wookyun Kho, co-founder of MediBloc, said, “We are developing and operating a safe Panacea so that only patients who are willing to participate can participate in the study of infectious diseases while storing patient data in the SHINE app. As the current pandemic has lasted over two years so far, many medical staff and companies around the world are working together to end this situation, and I’m glad MediBloc can contribute and engage as an IT medical company. We will do our best to develop and operate Panacea to contribute to global health.”
Our team will continue to expand our business globally and accelerate the commercialization of the MediBloc platform. We appreciate everyone’s continued support!